

October 24, 2024

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Outcome of Board Meeting held on October 24, 2024**

**Ref: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

We wish to inform you that Board of Directors of Strides Pharma Science Limited (“**the Company**”) in their meeting held today i.e., October 24, 2024 considered and approved the re-appointment of Dr. Kausalya Santhanam as an Independent Director of the Company for a second term, based on the recommendation of Nomination and Remuneration Committee.

Dr. Kausalya Santhanam (DIN: 06999168) is being re-appointed, as an Independent Director of the Company, for a second term of five years from December 11, 2024 upto December 10, 2029 (both days inclusive), subject to the approval of the shareholders of the Company.

Disclosure under Regulation 30 is enclosed as **Annexure 1**.

The Board Meeting commenced at 11:15 hrs IST and concluded at 13:10 hrs IST.

This is for your information and record.

Thanks & Regards,  
For **Strides Pharma Science Limited**,

\_\_\_\_\_  
**Manjula Ramamurthy**  
**Company Secretary**  
**ICSI Membership No. A30515**



Encls. As above

**Disclosure under Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR) and SEBI Circular bearing reference SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 dated July 13, 2023**

**Re-appointment of Dr. Kausalya Santhanam as an Independent Director**

#	Particulars	Remarks
1	Name of Director	Dr. Kausalya Santhanam
2	Reason for change viz., appointment, resignation, removal, death or otherwise	<p>Dr. Kausalya's first term as Independent Director is expiring on December 10, 2024.</p> <p>Pursuant to recommendation of Nomination and Remuneration Committee and approval of Board of Directors of the Company at their meeting held on October 24, 2024, Dr. Kausalya Santhanam is re-appointed as Independent Director of the Company for a second term of 5 years commencing from December 11, 2024, subject to approval of shareholders of the Company.</p>
3	Date of appointment/ cessation (as applicable) & terms of appointment	Second term of 5 years commencing from December 11, 2024.
4	Brief Profile (in case of appointment)	<p>Dr. Kausalya, aged about 56 years, is a Patent attorney registered with the Indian Patent Office as well as the US Patent and Trademark Office and is the Founder of SciVista IP &amp; Communication.</p> <p>Dr. Kausalya has a Ph.D in Cell biology and Immunology from Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh. Her Post-Doctoral training was in Cancer Biology at Center for Cellular and Molecular Biology (CCMB), Hyderabad. Later she was a National Research Council (NRC) Fellow at Walter Reed Army Institute of Research, Washington DC and then a Research Associate at Albert Einstein College of Medicine, New York. Later, she worked for five years as an in-house counsel in the Intellectual Property Department of CuraGen Corporation, a Biopharmaceutical company at Connecticut, USA.</p>

		<p>Dr. Kausalya serves as Independent Director on the Boards of various Pharma and Animal Health Companies.</p> <p>At Strides, Dr. Kausalya is the Chairperson of the CSR Committee and Stakeholders Relationship Committee. She is also a member in Audit Committee, Nomination and Remuneration Committee and Risk Management Committee.</p>
5	Disclosure of relationship between directors (in case of appointment of Director)	Dr. Kausalya is not related to any of the Directors of the Company.
6	Other Directorship/ Memberships (in listed entities in case of resignation of Independent Director)	Not applicable
7	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively.	Dr. Kausalya is not debarred from holding office of a Director by virtue of any SEBI Order or any other such authority.

\*\*\*\*\*